ESSA Pharma Inc. EPIX
0.20 0.00 (+0.00%)
At closeOct 13, 2025, 4:00 PM EDT
0.2012 Day range 0.2012
52-week range unavailable
Analyst view
Price target (mean) 9.19 +4467.8% upside
Now 0.2012
- Target (low)
- 1.65
- Target (mean)
- 9.19
- Target (high)
- 30.99
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.255 | -0.259 – -0.251 | -0.18815 | -35.5% | 0 | 0.0% | 2 |
| Next quarter | -0.1635 | -0.216 – -0.111 | -0.27299 | +40.1% | 0 | 0.0% | 2 |
| Current year | -0.6685 | -0.92 – -0.432 | -0.91098 | +26.6% | 0 | 0.0% | 4 |
| Next year | -0.44075 | -1.06 – 0.223 | -0.6685 | +34.1% | 7.76M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2024 | Piper Sandler | Downgrade | Overweight | Neutral |
| Nov 4, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 1, 2024 | Jones Trading | Downgrade | Buy | Hold |
| May 16, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 13, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 9, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| May 12, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 17, 2021 | Oppenheimer | Maintained | — | Outperform |
| Mar 4, 2021 | Piper Sandler | Initiated | — | Overweight |
| Feb 25, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 11, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 11, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 25, 2019 | Oppenheimer | Initiated | — | Outperform |
| Mar 26, 2018 | HC Wainwright & Co. | Initiated | — | Buy |